AMAG Pharmaceuticals Announces U.S. Launch of Feraheme (Ferumoxytol) Injection

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Feraheme (ferumoxytol) Injection is now available for commercial sale in the United States. Feraheme is an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. Feraheme can provide patients with a 1 gram therapeutic course of iron in two 510 mg IV injections administered as quickly as 17 seconds each, within one week. Feraheme was approved by the U.S. Food and Drug Administration on June 30, 2009.

The Company will be marketing and selling Feraheme in the U.S. through its commercial organization consisting of approximately 150 seasoned professionals, including an 80-person specialized sales force, an experienced account management and reimbursement team, and a contract nurse team. The wholesale acquisition cost (WAC) of Feraheme is $396.78 per 510 mg vial.



Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Trump wants more mental health care; Alabama says it's trying